🆕🗞️Hot off the press! Nature Medicine #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽 More to come with the randomized study📚✔️! Opens to doors to off the shelf vaccine for so many patients with KRAS/NRAS mutations. OncoAlert 🔗nature.com/articles/s4159…

Join Our Collaborators at Springer Health+ IME to explore this new, FREE clinical pathway tool designed to help you detect and target NTRK fusions🧬 & HER2 mutations in #NSCLC 🫁 #LungCancer CLICK HERE👉buff.ly/FeMbJ0r Developed and led by global experts, this evidence-based

Out in The Breast Online our survey to physicians👨🏻‍⚕️& patients👩🏼on screening for brain metastases in pts with #breastcancer🧠 Proud of this international collaboration with colleagues and friends towards better care for pts with brain mets! OncoAlert doi.org/10.1016/j.brea…

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy buff.ly/v90Gufj Large

Join us for the 44th Annual Congress of the European Society of Surgical Oncology (ESSO 44) European Society of Surgical Oncology (ESSO) Gothenburg, Sweden🇸🇪 15 to 17 October 2025 REGISTER HERE 👉 buff.ly/a5WaGmM We invite researchers, clinicians, and residents to attend and take part of the

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive #BladderCancer : A Phase 2 Trial sciencedirect.com/science/articl… This single-center phase 2 trial investigated neoadjuvant

Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨 buff.ly/KVngjav Join leading experts for two days of case-based learning, interactive panels, and

🚨This cohort study found that women who underwent implant-based breast reconstruction after mastectomy had a higher risk ⚠️ of both B- and T-cell #lymphomas of the breast 🎀 Read more 👉jamanetwork.com/journals/jaman… OncoAlert JAMA Oncology #Oncology

High circulating IL-6/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in advanced renal cell carcinoma patients treated with PD-1 blockade aacrjournals.org/clincancerres/… The phase II NIVOREN GETUG-AFU-26 trial evaluated nivolumab in a real-world cohort of 353

Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment mdpi.com/1422-0067/26/1… This review explores advances beyond prostate-specific antigen (PSA) in the detection and management of localized #ProstateCancer , focusing on emerging urinary biomarkers (PCA3,

You're invited to join the Post #ASCO25 Skin Cancer Highlights webinar ON Demand WATCH HERE👉 buff.ly/XWgvcPU hosted by VJ Oncology and Featuring expert presentations and in-depth discussions on key abstracts in Skin cancer presented at ASCO 2025. Chaired by Dr

Register for free at tinyurl.com/edhvcb28 and check out the recording of our case-based #BreastCancer webinar! 🧑‍⚕️ With drs. Fatima Cardoso, Véronique Diéras, Elisa Agostinetto and Nicolò Battisti, MD ➡️ On the management of HER2+ metastatic BrCa

New #glioblastoma (GBM) phase 2 study results: The combination of lenvatinib plus pembrolizumab demonstrated antitumor activity in a small subpopulation of participants with recurrent GBM as second-line or later treatment. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert #NeuroOnc

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer buff.ly/M7MH7Xa Invasive lobular carcinoma (ILC), the second most common #BreastCancer subtype, is now recognized as a distinct disease with unique diagnostic and management

A warm invite to all of our GU Colleagues to attend IN PERSON OR ONLINE (HYBRID) To the International Urology Cancer Summit🇬🇧 in Portsmouth!! REGISTER HERE👉 buff.ly/yLSE62j The International Urology Cancer Summit is a FREE, independent educational event for all

#GIonc in JAMA Oncology #ACCORD trial: Adjuvant camrelizumab + chemoradiation vs observation in resected EHC/GBC (n=93) #hpbcsm ⬆️ #OS (3y 58% vs 31%) + #RFS (3y 40% vs 17%) ⬇️ #tox Synergistic over chemo alone 💉☢️ 🔗: jamanetwork.com/journals/jamao… Sakti Chakrabarti, MD Ryan Nipp, MD, MPH, MBA, FASCO Supriya peshin

New: Peritransplant lysine methyltransferase 2a–rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 8-14, 2025 ⭐️REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Ping COR2ED VJ Oncology Advanced Prostate Cancer Consensus Conference Mirrors of Medicine Springer Health+ PER high5md

🔝🔝🔝 A must-watch OncoAlert WEEKLY RoundUp! 📲 Register: OncoAlert360.com Key 🔑 updates from Aug 8–14: ✅ Extending ET in early breast cancer ✅ Nemvaleukin in melanoma ✅ New targets in prostate & GI cancers ✅ Real-world pancreatic cancer data …and more!

Biomarkers from adjuvant nivolumab(PD-1) vs placebo in UC shows ⬆️ TC PD-L1, CD4/8, IFNγ,TMB/APOBEC in responders & ⬆️TGFb in resistance Matt Galsky Nature Medicine These result overlap with Avelumab in M1 disease (PD-L1) suggesting aligned but multifactorial response mechanisms.